Sanctura Once-Daily NDA Touts “Landmark Tolerability”
This article was originally published in The Pink Sheet Daily
Executive Summary
Indevus will position the XR version of its incontinence therapy based on its low incidence of dry mouth.
You may also be interested in...
Sanctura XR NDA Filing On Target For Year-End
Indevus reports Phase III trial results confirming earlier data demonstrating the efficacy of the once-daily overactive bladder treatment.
P&G Joins Novartis’ Efforts To Market Overactive Bladder Treatment Enablex
Co-promotion agreement leaves the door open for P&G and Novartis to solicit FDA for approval of Enablex as OTC. Deal brings expanded sales force in a crowded market.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.